ABSTRACT
https://s3-euw1-ap-pe-df-pch-content-public-p.s3.eu-west-1.amazonaws.com/9781003381976/411d9bae-2b00-498d-8eeb-34f6ab782298/content/ufig14_1.tif" xmlns:xlink="https://www.w3.org/1999/xlink"/> https://s3-euw1-ap-pe-df-pch-content-public-p.s3.eu-west-1.amazonaws.com/9781003381976/411d9bae-2b00-498d-8eeb-34f6ab782298/content/ufig14_2.tif" xmlns:xlink="https://www.w3.org/1999/xlink"/> As our discussions progressed, we would keep finding challenges to commercialization for companies in life sciences. When it made sense, we integrated them in their relevant section, but for a few, their diversity made them quite eclectic. Hence, we decided to take a simpler approach and introduce them in a consolidated chapter. We will be giving our points of view on commercialization challenges related to digital health, quick thoughts on the role of regulatory frameworks, some thoughts on social media and on AI and life sciences.
